Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tabimorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR known ✓ | Q92847 | 8/20 | 0.65 |
| ▸ | FCER2 | P06734 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tabimorelin SCHEMBL29440097 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| SCHEMBL6316837 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL29899698 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL209442 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL13575741 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL209441 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| SCHEMBL6316843 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL4435323 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL22345096 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL29958795 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-8450268-B2 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| US-6281247-B1 | GLANDULAR DISORDERS; ANIMAL GROWTH REGULATORS | NOVO NORDISK A/S (DK) | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | CRH, PYGB, CHAT | GHSR 10/4885FCER2 2112/4885MMP9 4637/4885 |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | ATP6V1B2, GHSR, CRH | GHSR 2/4885FCER2 2993/4885MMP9 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.